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Abstract
Background: TGR5, the G protein-coupled bile acid receptor 1 (GPBAR1), has been linked to inflammatory pathways as well
as bile homeostasis, and could therefore be involved in primary sclerosing cholangitis (PSC) a chronic inflammatory bile duct
disease. We aimed to extensively investigate TGR5 sequence variation in PSC, as well as functionally characterize detected
variants.
Methodology/Principal Findings: Complete resequencing of TGR5 was performed in 267 PSC patients and 274 healthy
controls. Six nonsynonymous mutations were identified in addition to 16 other novel single-nucleotide polymorphisms. To
investigate the impact from the nonsynonymous variants on TGR5, we created a receptor model, and introduced mutated
TGR5 constructs into human epithelial cell lines. By using confocal microscopy, flow cytometry and a cAMP-sensitive
luciferase assay, five of the nonsynonymous mutations (W83R, V178M, A217P, S272G and Q296X) were found to reduce or
abolish TGR5 function. Fine-mapping of the previously reported PSC and UC associated locus at chromosome 2q35 in large
patient panels revealed an overall association between the TGR5 single-nucleotide polymorphism rs11554825 and PSC
(odds ratio = 1.14, 95% confidence interval: 1.03–1.26, p = 0.010) and UC (odds ratio = 1.19, 95% confidence interval 1.11–
1.27, p = 8.561027), but strong linkage disequilibrium precluded demarcation of TGR5 from neighboring genes.
Conclusions/Significance: Resequencing of TGR5 along with functional investigations of novel variants provided unique
insight into an important candidate gene for several inflammatory and metabolic conditions. While significant TGR5
associations were detected in both UC and PSC, further studies are needed to conclusively define the role of TGR5 variation
in these diseases.
Citation: Hov JR, Keitel V, Laerdahl JK, Spomer L, Ellinghaus E, et al. (2010) Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing
Cholangitis. PLoS ONE 5(8): e12403. doi:10.1371/journal.pone.0012403
Editor: Pieter H. Reitsma, Leiden University Medical Center, The Netherlands
Received April 18, 2010; Accepted July 14, 2010; Published August 25, 2010
Copyright:  2010 Hov et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Norwegian PSC research center, Research Council of Norway, the Deutsche Forschungsgemeinschaft through
Sonderforschungsbereich 575 Du¨sseldorf ‘‘Experimental Hepatology’’ and Klinische Forschergruppe-217 Du¨sseldorf ‘‘Hepatobiliary transport and liver disease’’
and the German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN), the Popgen biobank, the DFG excellence
cluster ‘‘Inflammation at Interfaces’’ and the Integrated Research and Treatment Center - Transplantation (reference number: 01EO0802). The 1958 British Birth
Cohort collection is funded by the United Kingdom Medical Research Council (MRC, grant G0000934) and The Wellcome Trust (grant 068545/Z/02). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12403
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: j.e.r.hov@medisin.uio.no
" Full list of members is available in Note S1.
Introduction
TGR5, the G protein-coupled bile acid receptor 1 (GPBAR1),
was recently identified as the first plasma membrane-bound bile
acid receptor [1,2]. TGR5 is strongly expressed in monocytes and
macrophages, and the receptor has been shown to inhibit the
release of inflammatory cytokines from activated macrophages
[2,3]. A role in bile homeostasis and metabolic regulation is
suggested by TGR5 knockout mice, which are resistant to
gallstones and obesity [4–7]. In the hepatobiliary system, TGR5
protein expression has been demonstrated in rodent Kupffer cells,
liver sinusoidal endothelium and biliary epithelium [3,8]. Inves-
tigations in humans have so far been limited to the gallbladder,
where TGR5 is co-localized with the cystic fibrosis transmem-
brane conductance regulator (CFTR) [9]. Stimulation of TGR5 in
gallbladder cells activates CFTR [9], suggesting that the secretory
functions of cholangiocytes may be regulated by this interaction.
Given the bile acid specificity and involvement in inflammatory
pathways, TGR5 is a plausible candidate for involvement in
hepatobiliary diseases. Primary sclerosing cholangitis (PSC) is a
chronic inflammatory condition of the intra- and extrahepatic bile
ducts with a prevalence of approximately 10 per 100,000 in
Western countries [10,11]. PSC is strongly linked to inflammatory
bowel disease, which affects up to 80% of the patients [12], most
often classified as ulcerative colitis (UC), a chronic inflammatory
disease of the colonic mucosa [13]. The etiology of PSC and the
link to intestinal inflammation is poorly understood [14], but a role
of genetic factors in the pathogenesis is likely [15]. TGR5 function
has so far not been investigated in PSC, but given the interaction
with CFTR, it is interesting that cystic fibrosis (caused by CFTR
mutations) may involve liver disease, often resembling PSC [16].
Intriguingly, induction of colitis in Cftr knockout mice leads to bile
duct injury [17], and reduced CFTR function have been reported
in PSC patients [18,19], even in the absence of CFTR mutations
[19]. Thus, intestinal inflammation seems to increase vulnerability
to biliary injury when CFTR function is impaired, and TGR5
could be speculated to be involved.
Little is known about the details of TGR5 structure and how
mutations affect function. Whether sequence variation may confer
disease susceptibility is also not known. However, the gene is located
at a chromosomal region (2q35), close to the single-nucleotide
polymorphism (SNP) rs12612347 that we recently found associated
with both UC [replication OR=1.18 (1.0821.28) p= 2.061024]
and PSC [in a substudy assessing UC findings in PSC, OR=1.26
(1.0621.50), p = 0.0088] in genome-wide association studies
[20,21]. Further investigation of this locus has so far not been
performed. Given the potential role of TGR5 in bile homeostasis
and inflammation, we aimed to make a detailed genetic and
functional characterization of TGR5 in PSC, and in parallel assess
its possible association with PSC and UC.
Materials and Methods
Ethics Statement
This study was approved by the Regional Committee for
Medical Research Ethics, South-Eastern Norway, in addition to
approval from the ethics committees at all involved centers.
Written informed consent was obtained from all participants.
Subjects
A total of 267 Norwegian PSC patients and 274 healthy controls
were included for sequencing of TGR5 (Table 1). The PSC
patients were recruited on admission to Oslo University Hospital
Rikshospitalet, while healthy controls were randomly selected from
the Norwegian Bone Marrow Donor Registry (NORDONOR).
The diagnosis of PSC was based on standard clinical, biochemical,
histological and cholangiographic criteria [22]. The diagnosis of
inflammatory bowel disease was based on clinical, radiological,
histological, and endoscopic (i.e. type and distribution of lesions)
criteria [23].
A total of 1109 PSC patients (69% male, 73% with concomitant
inflammatory bowel disease), 2761 UC patients (47% male) and
4697 healthy controls were available for genotyping (including the
sequenced individuals). These came from Norway and Sweden
(panel 1), Belgium and the Netherlands (panel 2), Germany (panel
3) and the United Kingdom (panel 4). Details are described in
Materials and Methods S1, including the extent of overlap
between the patient panels in the present study and those used in
the previous genome-wide association studies. For fine-mapping, a
total of 285 Norwegian PSC patients, 882 German and British
patients with UC and 2496 healthy controls (subsets of panel 1, 3
and 4) were genotyped.
TGR5 Resequencing
In order to include all TGR5 transcript variants so far reported,
the entire TGR5 and 1,589 basepairs of the 59 region were covered
by nine primer pairs (Figure 1 and Table S1). For amplification, a
standard touchdown PCR was applied using Taq Gold (Applied
Biosystems). A 25 mL reaction contained 2.5 mL610 buffer, 3 mL
MgCl2, 0.5 mL dNTPs (10 mM), 0.4 mL forward primer (10 mM),
0.4 mL reverse primer (10 mM), 0.15 mL taq, 13.05 mL water and
5 mL DNA input (1 ng/mL). The PCR program was as follows:
95uC for 12 min, (95uC for 30 sec, Tm for 30 sec, 72uC for
30 sec)616 cycles [td 20.5uC], (95uC for 30 sec, Tm28uC for
30 sec, 72uC for 30 sec)619 cycles, 72uC for 10 min, 10uC for ‘.
Sequencing was performed using BigDyeTM chemistry (Applied
Biosystems) according to standard manufacturer’s instructions. All
sequences were inspected for SNPs, insertions and deletions in
both SeqScape v2.5 (Applied Biosystems) and novoSNP v3.0 [24].
All assigned SNPs were observed in both forward and reverse
sequences.
Genotyping
Based on significant associations in UC and PSC genome-wide
association studies [20,21], a 238 kilobasepairs large genetic region
was selected for fine-mapping. A HapMap tagging approach was
combined with the addition of associated SNPs from the UC study
[20] and hand-picked non-HapMap SNPs. A total of 45 SNPs
passed assay design and were genotyped using ligation-based
SNPlexH genotyping (Applied Biosystems, Foster City, CA, USA)
as described elsewhere [25–27]. Rs11554825 was genotyped using
a TaqManH assay (Applied Biosystems). Only SNPs with minor
allele frequencies .0.01, genotyping success rate .0.95 and no
significant deviation from Hardy-Weinberg equilibrium in the
healthy controls (P.0.01) were included for association analysis.
TGR5 in PSC
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12403
TGR5 Structural Modeling and Sequence Data Collection
Publicly available database resources provided by the Ensembl
project (http://www.ensembl.org), the DOE Joint Genome
Institute (http://genome.jgi-psf.org), the UniProt Consortium
(http://www.uniprot.org), and the NCBI (http://www.ncbi.nlm.
nih.gov) were searched for homologs of human TGR5. Multiple
sequence alignments (MSAs) were generated with Muscle [28],
TCoffee [29], MCoffee [30], and Expresso [31], and the MSAs
were viewed and manipulated in Jalview [32]. Structural disorder
predictions were generated with DISOPRED2 (http://bioinf.cs.
ucl.ac.uk/disopred) [33]. A model for the structurally ordered
segments of TGR5 was generated from a template 3EML from the
Protein Data Bank (http://www.pdb.org) employing standard
homology modeling with SwissModel [34]. 3EML is the
experimental structure of human adenosine A2a receptor from
Jaakola et al. [35].
Cloning and Mutagenesis of Human TGR5
Human TGR5 was cloned from liver cDNA as previously
described [9] (details in Materials and Methods S1). Three
different plasmids were generated: 1) TGR5 only, containing the
entire coding sequence including the stop codon (pcDNA3.1+
vector, Invitrogen, Karlsruhe, Germany), 2) TGR5-yellow fluo-
rescent protein (TGR5-YFP), containing the coding sequence with
a C-terminal YFP-tag (pEYFP-N1 vector, Clontech, Palo Alto,
CA, USA), and 3) FLAG-TGR5-YFP, containing the coding
sequence with an N-terminal FLAG-tag and a C-terminal YFP-tag
(pEYFP-N1). Mutations were introduced using the Multisite-
mutagenesis kit (Stratagene, La Jolla, CA, USA). Successful
cloning and mutagenesis was verified by sequencing.
Immunofluorescence Staining
HEK293 (CRL-1573) and MDCK (CCL-34) cell lines were
obtained from American Type Culture Collection (Manassas, VA,
USA). Both HEK293 (grown on glass coverslips) and MDCK
(grown on filterwells) cells were transiently transfected with TGR5
constructs using LipofectAMINE-2000 (Invitrogen). After 48 h
cells were fixed in 100% methanol (220uC, 5 min), immuno-
stained and analyzed on a Zeiss LSM510META confocal
microscope using a multitracking modus. A 63x objective and a
scanning resolution of 102461024 pixels was used for all samples.
The following antibodies were used: M39 (TGR5) 1:500, Na+/
K+ATPase (Sigma, Taufkirchen, Germany) 1:100, anti-FLAG-M2
(Sigma) 1:250. Fluoresceine and Cyanine-3 conjugated secondary
antibodies (Dianova, Hamburg, Germany) were diluted 1:100 and
1:500, respectively. Nuclei were stained with Hoechst (1:20.000;
Invitrogen).
Flow Cytometry
In order to quantify protein expression and plasma membrane
localization, flow cytometry was performed. HEK293 cells were
transiently transfected with the TGR5-YFP or FLAG-TGR5-YFP
constructs. After 48 h cells were washed with ice-cold phosphate-
buffered saline (PBS), detached by pipetting with 1 ml PBS,
centrifuged (2,000 g for 3 min at 4uC), resuspended in PBS, and
washed twice by centrifugation and resuspension. For measure-
Table 1. Characteristics of resequenced individuals.
PSC (n=267) Healthy controls (n =274)
Age at diagnosis, median (range) 33 (12273) 32* (18246)
Male sex, n (%) 196 (73) 157 (57)
Inflammatory bowel disease, n (%) 214 (80) -
Cholangiocarcinoma, n (%) 27 (10) -
Liver transplanted or deceased, n (%) 130 (49) -
Transplantation as primary endpoint, n (%) 87 (33) -
Observation time to transplantation or death (years), median (range) 8 (0232) -
*Age at sampling.
doi:10.1371/journal.pone.0012403.t001
Figure 1. Resequencing of TGR5. The sequenced region of TGR5, covering chromosome 2 positions 218,832,394–218,836,917 (NCBI build 36),
which includes two exons and the 59untranslated region (59UTR), where an alternative transcript has been reported. The coding part of TGR5 is
entirely in exon 2 (thick section). Identified single-nucleotide polymorphisms (SNPs, Table 2) are represented by red dots, and the common SNPs and
nonsynonymous mutations are named. The nine amplicons used for sequencing is illustrated below, covering a total of 4524 basepairs non-
overlapping sequence with an average amplicon overlap of 174 basepairs.
doi:10.1371/journal.pone.0012403.g001
TGR5 in PSC
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ment of transfection efficacy and protein expression, cell size
(forward scatter), granularity (sideward scatter), and fluorescence
were analyzed in 50,000 cells using a FACS-CANTO-II (BD
Biosciences, Heidelberg, Germany). Cells with YFP-fluorescence
greater than 103 were gated and denoted as TGR5-YFP-
transfected cells. TGR5 protein expression was measured as mean
fluorescence intensity per transfected cell (using the BD FACSDiva
Software), normalized to wild-type.
Plasma membrane expression was quantified by determining
the amount of the FLAG-tag on the extracellular surface and
normalizing to the total amount of TGR5 (determined by YFP-
fluorescence): Anti-FLAG M2 was labeled with PacificBlue
conjugated anti-mouse IgG-Fab-fragments using the Zenon
PacificBlue Label-Kit (Invitrogen). Cells were incubated 30 min
(4uC) with the labeled antibody (1:250). Afterwards cells were
washed twice with ice cold PBS and measured for forward scatter,
sideward scatter, YFP- and PacificBlue-fluorescence. The follow-
ing controls were used: Unlabeled non-transfected cells (no
fluorescence); unlabeled FLAG-TGR5-YFP transfected cells (only
YFP-fluorescence), labeled FLAG-TGR5-Q296X transfected cells
(only PacificBlue-fluorescence). The amount of TGR5 in the
plasma membrane was determined as the amount of PacificBlue-
YFP-positive cells divided by the total amount of YFP-positive
cells. As control, detection of every YFP-positive cell with the anti-
FLAG antibody in permeabilized cells was performed: Detached
cells were fixed in 4% paraformaldehyde (15 min at room
temperature), washed with PBS and permeabilized using 0.1%
Triton-X (5 min). Afterwards cells were washed twice, incubated
with the labeled anti-FLAG-M2 antibody, washed again and
analyzed.
Measurement of cAMP
Receptor activity was investigated using the TGR5 agonist
taurolithocholic acid (TLC) [36]. HEK293 cells were cotrans-
Table 2. Single-nucleotide polymorphisms (SNPs) detected at the TGR5 locus by complete resequencing of the gene (exons,
introns, and untranslated regions) in 267 Norwegian PSC patients and 274 healthy controls.
dbSNP ID/name Chromosome 2 position* Alleles Category Minor allele count (frequency)
PSC Controls
rs3731859 218,832,467 A/G 59UTR 245 (0.46) 223 (0.41)
TGR5snp1 218,832,492 C/T 59UTR 2 1
TGR5snp2 218,832,779 C/T 59UTR 1 1
rs13003334 218,833,166 A/T 59UTR 241 (0.45) 222 (0.41)
TGR5snp3 218,833,670 A/G 59UTR 0 1
rs11554825 218,834,054 T/C Exon 1 untranslated 246 (0.46) 225 (0.41)
TGR5snp4 218,834,358 G/T Intron 1 0
TGR5snp5 218,834,372 G/A Intron 1 9
TGR5snp7 218,834,433 G/T Intron 11 (0.02) 12 (0.02)
TGR5snp6 218,834,814 A/T Intron 0 1
rs1567869 218,834,980 T/C Intron 12 (0.02) 12 (0.02)
TGR5snp8 218,835,162 G/C Exon2 untranslated{ 1 1
TGR5snp9 218,835,335 C/T Exon2 untranslated{ 0 1
TGR5snp10 218,835,416 G/A Exon2 untranslated{ 1 0
TGR5snp11 218,835,569 G/A Exon2 untranslated{ 0 1
rs57621524 218,835,654 C/T Exon 2 untranslated 1 0
rs56192869 218,835,662 G/A Exon 2 untranslated 1 0
TGR5snp12 218,835,744 T/C Exon 2 synonymous 0 1
TGR5snp21 218,835,938 T/C W83R 1 0
TGR5snp22 218,836,149 C/T A153V 1 0
TGR5snp13 218,836,223 G/A V178M 1 0
TGR5snp14 218,836,327 C/T Exon 2 synonymous 5 4
TGR5snp15 218,836,339 G/C Exon 2 synonymous 11 (0.02) 12 (0.02)
TGR5snp16 218,836,340 G/C A217P 1 3
TGR5snp17 218,836,505 A/G S272G 1 0
TGR5snp18 218,836,577 C/T Q296X 0 1
TGR5snp19 218,836,740 C/G Exon 2 untranslated 3 2
rs2292549 218,836,750 T/C Exon 2 untranslated 12 (0.02) 12 (0.02)
TGR5snp20 218,836,759 C/T Exon 2 untranslated 11 (0.02) 12 (0.02)
*NCBI build 36.
{Resides in exon 2 as depicted in Figure 1, but shorter variants of exon 2 (which do not include the affected nucleotide) have been reported. Alleles = major/minor allele
defined from positive strand. 59UTR = 59 untranslated region.
doi:10.1371/journal.pone.0012403.t002
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fected with a cAMP-sensitive reporter gene construct (Bayer AG,
Leverkusen, Germany) and TGR5 variants in pcDNA, using
LipofectAMINE as described [8]. Control experiments were
performed with the empty pcDNA vector. Luciferase assays were
carried out with Dual-Luciferase kit (Promega, Madison, WI,
USA), and luciferase activity was normalized to transfection
efficacy, using cotransfection of a Renilla expression vector.
TGR5 Transcription
Expression data for TGR5 (GPBAR1) in EBV-transformed
lymphoblastoid cell lines from the HapMap samples was available
from the GENEVAR project [37], and expression in the n= 210
non-related individuals were correlated to SNP genotypes, using
linear regression in an in-house web-based tool SNPEXP v1.1
(http://app3.titan.uio.no/biotools/tool.php?app=snpexp).
Statistical Methods
In vitro experiments were performed independently at least four
times. Results were expressed as means6standard error of the
mean, and analyzed using two-sided t-tests. P,0.05 was
considered statistically significant. SNP data were analyzed using
Plink v1.06 [38] and Haploview v4.1 [39]. Allele frequencies were
compared with chi-square tests or the Cochran-Mantel-Haenszel
(CMH) test (across multiple panels). Heterogeneity of the odds
ratios (ORs) of the panels was assessed with the Breslow-Day test.
In order to control for the effect of rs11554825, logistic regressions
were performed using Plink conditioning on rs11554825 with
inclusion of study panel as a covariate. Linkage disequilibrium
(LD) was calculated in healthy controls.
Results
Resequencing and Three-Dimensional Modeling of TGR5
Resequencing of the TGR5 gene in 267 Norwegian PSC
patients and 274 healthy controls revealed a total of 29 SNPs
(Table 2 and Figure S1). Twenty-two out of 29 were previously not
described in any database (novel), and six of these 22 were
nonsynonymous. Four nonsynonymous mutations were found in
PSC patients only (W83R, A153V, V178M and S272G), one in
both a PSC patient and three healthy controls (A217P), and one in
Figure 2. Structure and residue conservation for the family A type G-protein-coupled receptor TGR5. Panel A shows the 3D structure
of TGR5 as determined by comparative modeling. The receptor comprises seven transmembrane helices (TMH1-7), three extracellular loops (ECL1-3),
contributing to ligand binding, and three intracellular loops (ICL1-3) involved in mediating the signal to downstream signaling molecules. ICL3 and
the N- and C-terminal segments are structurally flexible and disordered (broken lines). Panel B shows the location of the six residues found to be
mutated in PSC patients and healthy controls. Evolutionary conservation in sequence segments containing the residues found to be mutated is
shown in Panel C for a number of mammalian (Homo sapiens, Mus musculus, Canis familiaris, Bos taurus, and Monodelphis domestica) and other
vertebrate species (Anolis carolinensis, Xenopus tropicalis, and Oryzias latipes).
doi:10.1371/journal.pone.0012403.g002
TGR5 in PSC
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a healthy control only (Q296X). Of non-coding variants, three
common SNPs in strong LD were detected, of which rs11554825
was located in the untranslated TGR5 exon 1, while rs3731859
(r2 = 0.99 with rs11554825) and rs13003334 (r2 = 0.97 with
rs11554825) were located in and near a reported transcript in
the 59 untranslated region (Figure 1).
TGR5 is conserved in mammals and other vertebrates. Since a
molecular structure of TGR5 was not available, a structural model
was generated by comparative modeling in order to predict the
role of the nonsynonymous mutations (for details see Results S1).
The model shows the seven transmembrane helices standard for G
protein-coupled receptors (GPCRs) and a short intracellular C-
terminal a-helix (Figure 2A). Residues affected by nonsynonymous
mutations were distributed in all parts of the receptor. W83R and
A153V were localized in extracellular loops, V178M and S272G
in the transmembrane segments and A217P and Q296X in
intracellular loops (Figure 2B). These substituted residues were in
general conserved in mammals, except Ala153 not conserved in
bovine and Ala217 not conserved in guinea-pig (Figure 2C, Figure
S2 and Figure S3). Gln296 was not conserved, but Q296X stops
the translation of several conserved C-terminal residues.
Expression and Function of Mutated TGR5
In order to investigate the effect on receptor localization and
expression, the nonsynonymous mutations were introduced into
several different constructs and transfected into cell lines. Wild-type
TGR5 as well as the W83R, A153V, V178M, A217P and S272G
variants all localized to the plasma membrane irrespective of cell
line (MDCK or HEK293) or construct (TGR5-YFP, FLAG-TGR5-
YFP or TGR5) used, as shown in Figure 3A, Figure S4, Figure S5,
Figure S6 and Figure S7. Of particular importance is that TGR5
expressed without tags (Figure S6 and Figure S7) was localized
identically to tagged receptors, since tags may alter the localization
or function of proteins. When introducing the stop codon (Q296X),
the mutated protein was not detected by the TGR5 antibody, which
is directed against the C-terminus. Also, when using YFP-tagged
constructs, the Q296X mutation resulted in a non-detectable
truncated protein without YFP. However, by using an anti-FLAG
antibody, FLAG-Q296X-YFP could be detected in the endoplasmic
reticulum (ER) as demonstrated by the co-localization with
calnexin, a marker protein of the ER (Figure 3B/C).
Subsequently, the amount of protein produced and the
proportion actually localized within the plasma membrane, was
quantified using YFP-constructs and flow cytometry analysis in
non-permeabilized and permeabilized cells. Protein expression of
TGR5-W83R and TGR5-A217P was significantly reduced as
compared with wild-type TGR5 (Figure 4A), even though
transfection efficacy was similar for all constructs (Figure S8). In
HEK293 cells 89% of wild-type TGR5 was located in the plasma
membrane, which was similar for the W83R, A153V, V178M and
A217P variants, while TGR5-S272G showed significantly reduced
plasma membrane localization (80%, p= 0.025, Figure 4B).
TGR5 activity was analyzed using a cAMP-luciferase reporter
gene assay following stimulation with TLC, which is the most
potent endogenous agonist [36]. Forskolin increases cAMP
independently of TGR5 and was used as positive control. Wild-
type TGR5 exhibited high activity at 0.5 mM TLC and saturated
at 2.5 mM (Figure 5A). W83R and V178M showed a significant
Figure 3. Localization of TGR5 by confocal microscopy. In Panel A, polarized MDCK cells were transiently transfected with the different TGR5-
YFP variants including wild-type (TGR5-WT-YFP). All variants except TGR5-Q296X-YFP reached the plasma membrane, however TGR5-A217P-YFP and
TGR5-S272G-YFP were also present in some intracellular vesicles. In Panel B, MDCK cells were transiently transfected with FLAG-TGR5-YFP constructs
(wild-type and the Q296X mutant). The FLAG-tag was made visible using an anti-FLAG-M2 antibody (in red) and the yellow coloring in the overlay
image demonstrates that the FLAG antibody completely binds to the FLAG-TGR5-YFP wild-type protein both in the plasma membrane as well as in
intracellular vesicles (upper row). Introduction of the mutation Q296X leads to a premature stop codon and results in a truncated FLAG-Q296X-YFP
protein as demonstrated by the absence of the YFP-fluorescence, but by using the anti-FLAG antibody the truncated protein could be detected
(lower row). In Panel C, HEK293 cells were transiently transfected with the Q296X mutant of FLAG-TGR5-YFP (for the remaining variants, see Figure
S5). The truncated protein, stained with the anti-FLAG antibody, was almost completely retained in the endoplasmatic reticulum, as demonstrated by
the colocalization with the endoplasmatic reticulum marker calnexin. Nuclei were stained with Hoechst. Bars = 10 mm.
doi:10.1371/journal.pone.0012403.g003
Figure 4. Quantification of expression and localization of TGR5
variants. Panel A shows TGR5-YFP protein expression measured by
flow cytometry. Mean fluorescence intensity per transfected cell was
calculated, and expression of TGR5-WT-YFP (wild-type) was set to 1.0.
Untransfected cells (Co) served as controls. The protein expression
levels of the W83R (0.7760.02, n = 6) and A217P (0.7260.02, n = 6)
variants were reduced. Results are shown as mean6standard error of
the mean. ***Indicates significant difference (p,0.001) compared with
wild-type. Panel B shows membrane localization of FLAG-TGR5-YFP
variants as determined by flow cytometry. The N-terminal FLAG-tag is
localized extracellularly and can be labeled with antibodies only when
TGR5 is localized in the plasma membrane. The amount of receptor
within the plasma membrane was determined by dividing the amount
of FLAG-labeled TGR5 by the total amount of TGR5, as determined by
YFP-fluorescence. In HEK293-cells 8962% (n= 7) of wild-type was
located in the plasma membrane, which was similar to W83R, A153V,
V178M and A217P. The S272G variant showed significantly reduced
plasma membrane localization compared with wild-type (8063%,
n = 7). Results are shown as mean6standard error of the mean.
*Indicates significant difference (p,0.05) as compared with wild-type.
doi:10.1371/journal.pone.0012403.g004
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Figure 5. Activation of TGR5 variants by the bile acid taurolithocholic acid (TLC). HEK293 cells were cotransfected with TGR5 and a
reporter gene containing five cAMP responsive elements in front of the luciferase gene. Luciferase activity served as a measure of the rise in
intracellular cAMP following activation of TGR5. Forskolin (F, 10 mM) stimulated cAMP production independently of TGR5 and served as positive
control. Results are expressed as mean6standard error of the mean. *Indicates significant difference (p,0.05) as compared with TGR5 wild-type
(TGR5-WT). **p,0.01. ***p,0.001. In Panel A, activation of TGR5 wild-type (TGR5-WT) by TLC led to significant rises in luciferase activity already at a
concentration of 0.1 mM (n=14). Panel B and D show significantly reduced responses from TGR5-W83R (n = 4) and TGR5-V178M (n= 9) to 0.1, 0.5
and 2.5 mM TLC compared with TGR5-WT, while the responses to forskolin and 10 mM TLC were unaffected. The A153V variant did not affect receptor
activity (Panel C, n = 12).The A217P (Panel E, n = 6) and Q296X (Panel G, n = 7) variants completely lost responsiveness to TLC. Panel F shows the
S272G variant, which exhibited suppressed activation of luciferase by both forskolin and TLC at concentrations of 0.5, 2.5 and 10 mM (n=11).
doi:10.1371/journal.pone.0012403.g005
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reduction in activity at TLC concentrations between 0.1 and
2.5 mM, while activation by forskolin and 10 mM TLC were
unchanged (Figure 5B/D). The activity of A153V was similar to
wild-type (Figure 5C). The A217P and Q296X variants completely
abolished TGR5 responsiveness towards TLC with unaffected
activation by forskolin (Figure 5E/G). Introduction of S272G led
to significant reduction in luciferase activity following stimulation
with both forskolin and TLC (Figure 5F).
Genetic Associations at Chromosome 2q35
In parallel with TGR5 sequencing, fine-mapping at chromo-
some 2q35 was performed in PSC and UC. Figure 6A shows
overlapping and distinct peaks of statistically significant associa-
tions at chromosome 2q35 in SNP data from previous genome-
wide association studies in PSC and UC [20,21]. Further fine-
mapping in PSC and UC panels, including a joint PSC-UC meta-
analysis of the fine-mapped panels, was subsequently performed in
the peak region (Figure 6B). A high degree of LD was revealed,
meaning that alleles at TGR5 and several neighboring loci
occurred more frequently together than would have been expected
by chance (Figure 6B). A recombination hot-spot separated the
IL8RA and IL8RB genes from a LD block encompassing TGR5
and flanking genes, but further demarcation of a susceptibility
variant at chromosome 2q35 was not possible.
Following up on the findings from the TGR5 sequencing, the
only common exonic SNP in the gene was subsequently genotyped
in all available study panels. In the combined analysis in PSC
(1109 patients and 3593 healthy controls) and UC (2761 patients
and 4697 healthy controls), rs11554825 was associated with
both PSC (OR=1.14; 95% confidence interval: 1.03–1.26,
pCMH=0.010) and UC (OR=1.19; 95% confidence interval:
1.11–1.27, pCMH=8.5610
27), see Table 3 for allele frequencies.
The originally reported intergenic SNP at 2q35 (rs12612347)
[20,21] was associated at a similar level [PSC OR=1.15
(1.0521.27), pCMH=0.0044 and UC OR=1.19 (1.1121.28),
pCMH=5.6610
27]. The rs11554825 and rs12612347 SNPs were
in strong LD (r2=0.73), and logistic regression demonstrated that
the effects were not independent. However, when controlling for
the effect of rs11554825 (Figure 6B, highlighted in red) in the joint
PSC-UC analysis of the fine-mapping panels, three SNPs in LD
showed evidence of independent association (considering p,
0.05 as the threshold), with the lowest p-value at rs4674271
(prs11554825 = 0.0025, Results S1). These SNPs had minor allele
frequencies of 0.04–0.05 (in the healthy controls) and were in LD
with other low frequency SNPs throughout the locus (Figure 6B
and Results S1). In conclusion, the original reported association at
chromosome 2q35 may be caused by rs11554825, but several
independent variants could have an effect at this locus.
The effect of rs11554825 on TGR5 mRNA expression was
investigated in a publically available dataset from lymphoblastoid
cell-lines. Alleles at the PSC and UC associated rs11554825 were
in almost perfect LD with alleles at the 59untranslated region
(59UTR) rs3731859 (r2 = 0.99, Figure 1). There was a weak but
significant correlation between expression of TGR5 and
rs3731859 genotypes [r2 (explained variance) = 0.048, p =
0.0015, Figure S9]. The lowest expression was observed in
individuals homozygous for allele G, which was linked to risk
allele C at rs11554825.
Discussion
The dual function of TGR5 in biliary bicarbonate secretion and
Kupffer cell inhibition along with findings in previous genome-
wide association studies provided a strong rationale for the search
for novel genetic variants of TGR5 in PSC. Extensive resequencing
identified several nonsynonymous mutations, and the detected
effects on TGR5 structure, expression and function provide
Figure 6. Genetic analyses at chromosome 2q35. Panel A shows results from the association analysis (negative log10-transformed p-values
plotted on the vertical axis) of individual single-nucleotide polymorphisms (SNPs) at chromosome 2q35 in data sets from previous genome-wide
association studies (GWAS) in primary sclerosing cholangitis (285 patients and 298 healthy controls) and ulcerative colitis (1167 patients and 777
healthy controls) [20,21]. A linkage disequilibrium (LD) plot below shows pairwise LD (r2) between the SNPs, calculated in the healthy controls, where
increasing r2 values correspond to increasing LD. The shaded area covers the peak of associated SNPs corresponding to a region with strong LD.
Panel B shows fine-mapping of the shaded region in Panel A performed in three patient panels (details of the analysis are shown in Results S1). The
individuals in the PSC panel 1 subset (285 patients and 296 healthy controls) completely overlapped with the PSC GWAS in panel A, while the
individuals in the UC panel 3 subset (521 patients, 1096 controls) and UC panel 4 (361 patients, 1104 controls) were independent from the UC GWAS
in panel A. In addition to association analyses in the individual study panels, a PSC-UC meta-analysis of all fine-mapped patients (n = 1167) and
healthy controls (n = 2496) was performed. The fine-mapped region was characterized by strong LD, as shown in the lower plot, but a recombination
hot-spot was present between the IL8RA and IL8RB loci and the TGR5 (GPBAR1) locus and neighboring genes (ARPC2-TGR5-AAMP-TMBIM1-PNKD). The
meta-analysis p-value of the TGR5 exon 1 SNP rs11554825 is highlighted in red, while the shaded area in Panel B shows the resequenced region
covering TGR5.
doi:10.1371/journal.pone.0012403.g006
Table 3. Minor allele frequencies and association analysis of TGR5 SNP rs11554825.
Panel 1 Panel 2 Panel 3 Panel 4
n* n n n OR (95% CI) PCMH{
666/422/298 1095/331/583 1832/356/1519 1104/NA/361
Healthy controls 0.407 0.412 0.414 0.434
PSC 0.459 0.440 0.432 NA 1.14 (1.0321.26) 0.010
UC 0.471 0.429 0.463 0.475 1.19 (1.1121.27) 8.561027
*n: number of healthy controls/PSC patients/UC patients;
{Breslow-Day test yielded no evidence for heterogeneity of odds ratio (P-values 0.52 and 0.40, respectively). CI, confidence interval; OR, odds ratio (compared with
healthy controls); NA, not applicable; PCMH, p-value as calculated with Cochran-Mantel-Haenszel test across available panels; PSC, primary sclerosing cholangitis; UC,
ulcerative colitis.
doi:10.1371/journal.pone.0012403.t003
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valuable insight into the structural biology of the receptor. The
statistical associations detected for one exonic SNP in both PSC
and UC emphasize the possibility that TGR5 may influence
disease susceptibility in these conditions, but further studies are
required to exclude a role for neighboring genes.
GPCRs are important mediators of physiological responses, as
well as therapeutic targets [40]. It has proven very challenging to
resolve experimentally the molecular structure of GPCRs [40].
The structure-function relationship and effects of mutations are
therefore of great interest both for TGR5 and GPCRs in general.
One example is the A217P mutation, which caused a complete loss
of TGR5 activity as measured by the luciferase assay, pointing to a
crucial role of the third intracellular loop for TGR5 function. In
other GPCRs this loop has been found to be important for
interaction with the G protein [41], and interestingly, it is a key
target for a new class of GPCR specific agonists and antagonists
named pepducins [42]. The residues Trp83 and Val178 are both
conserved in mammals, and the mutations W83R and V178M led
to significantly reduced TGR5 response to TLC concentrations
(0.1–2.5 mM) close to the concentration known to induce half
maximal activity of wild-type TGR5 (0.29 mM) [36]. This reduced
activity corresponds to a right-shifted dose-response curve,
implying either reduced affinity or efficacy of the agonist. For
W83R this may be explained by the position of Trp83 in the first
extracellular loop, suggesting that the mutation affects ligand
binding. However, the accuracy of the receptor model in this part
of the molecule was too low to allow detailed studies of possible
mechanisms. The reduced activity of the V178M mutated protein
could possibly be explained by the localization of Val178 in the
fifth transmembrane helix, close to conserved residues involved in
propagation of conformational changes from the ligand-binding
pocket to the G-protein [43].
The S272G mutation abolished both responsiveness towards
TLC (TGR5 dependent) and forskolin (TGR5 independent),
suggesting altered interaction of TGR5 with downstream signaling
targets. Ser272 is conserved in all vertebrates and positioned in the
seventh transmembrane helix, likely to be important for
transmitting conformational changes. One possibility is that
S272G is an example of a constitutively active mutant, non-
responsive to ligands, which simultaneously diminishes the
response to forskolin by saturating adenylate cyclase [44]. The
A153V mutation appeared to be without functional consequences
when using TLC as agonist, but it can not be excluded that
mutation of this extracellular residue could affect the response to
other endogenous agonists. Although minor changes in TGR5
expression and plasma membrane localization were noted for
several mutations, the premature stop codon Q296X was the only
mutation with a major impact. By deleting 35 C-terminal residues,
it led to an almost complete retention of the receptor in the
endoplasmatic reticulum. This indicates that the cytoplasmic tail is
required for normal surface expression, in line with observations
made with the G protein-coupled angiotensin receptor AT1a [45].
In summary our results show that nonsynonymous mutations may
critically affect targeting of TGR5 to the membrane, agonist
binding, propagation of conformational changes through the
membrane, or intracellular signaling.
The TGR5 common SNP was statistically associated with both
PSC and UC in large European patient panels, but conclusive
evidence defining TGR5 as a disease gene in these conditions could
not be established. The main challenge was strong LD spanning
the locus, which is a common obstacle to the conclusive
identification of disease genes [46]. In addition there was statistical
evidence for independently associated risk variants at 2q35, but the
importance and nature of such variants can only be speculated
based on the present data. Regarding TGR5, further experimental
studies along with genetic mapping in other ethnicities will be
needed to overcome the limitations in present data. The important
notion that nonsynonymous mutations were observed in both PSC
patients and healthy controls is not surprising, since only
heterozygosity was observed, and genetically complex traits like
PSC and UC are caused by an interplay of multiple genetic
variants and environmental factors [47,48]. The mutations were
too rare to explain the statistical associations, but yielded an
opportunity to investigate the variable effects from naturally
occurring genetic variation.
For common variants, the biological effects are often weak
and difficult to elucidate, and the correlation between
expression levels of TGR5 and rs11554825 genotypes was not
strong, but still in line with recent findings in other diseases [49],
and could therefore be speculated to contribute to the
associations with PSC and UC. Furthermore, while the effect
size was weak in statistical terms (OR), the association may still
be important by suggesting an involvement of TGR5 related
pathways in PSC and UC [50]. Further exploration of the
implicated mechanisms of such an involvement may shed new
light on the role of bile acids in intestinal and biliary
inflammation, which could ultimately have therapeutic impli-
cations. This is particularly relevant for PSC, where no medical
treatment has yet been shown to influence progression to liver
cirrhosis and liver transplantation [51].
Supporting Information
Materials and Methods S1 Supporting information about the
subjects and the cloning and mutagenesis of human TGR5.
Found at: doi:10.1371/journal.pone.0012403.s001 (0.05 MB
DOC)
Results S1 Supporting results from the resequencing of TGR5,
the sequence collection, the structure modeling and the genetic
associations at chromosome 2q35.
Found at: doi:10.1371/journal.pone.0012403.s002 (0.09 MB
DOC)
Figure S1 Chromatograms from one heterozygote of each SNP
detected through resequencing of TGR5.
Found at: doi:10.1371/journal.pone.0012403.s003 (1.14 MB
DOC)
Figure S2 Multiple sequence alignment of human TGR5 and
orthologs (N-terminal half). Human TGR5 and orthologs from the
primates Pan troglodytes (chimpanzee), Pongo pygmaeus (orangutan),
Macaca mulatta (macaque), and Otolemur garnettii (bushbaby), other
mammals such as Oryctolagus cuniculus (rabbit), Cavia porcellus (guinea
pig), Dipodomys ordii (kangaroo rat), Mus musculus (mouse), Rattus
norvegicus (rat), Pteropus vampyrus (flying fox bat), Equus caballus
(horse), Dasypus novemcinctus (armadillo), Canis familiaris (dog), Bos
taurus (cow), Tursiops truncatus (dolphin), the marsupial Monodelphis
domestica (opossum), the lizard Anolis carolinensis, the frogs Xenopus
tropicalis and X. laevis, and the fish Oryzias latipes (medaka),
Gasterosteus aculeatus (three-spined stickleback), Takifugu rubripes
(fugu), and Tetraodon nigroviridis. Residues found to be mutated in
humans have been highlighted, and the Cys85-Cys155 disulfide
bridge has been indicated (dashed line).
Found at: doi:10.1371/journal.pone.0012403.s004 (3.55 MB TIF)
Figure S3 Multiple sequence alignment of TGR5 (C-terminal
half) from the same species as in Figure S2. Residues found to be
mutated in humans have been highlighted.
Found at: doi:10.1371/journal.pone.0012403.s005 (6.29 MB TIF)
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Figure S4 Localization of TGR5-YFP variants in HEK293 cells.
HEK293 cells were transiently transfected with the different
TGR5-YFP variants. An antibody against Na+/K+-ATPase was
used to stain the plasma membrane (shown in red). Nuclei were
stained with Hoechst (blue). A. Wildtype TGR5 (WT) was almost
completely targeted to the plasma membrane. B. The mutant
TGR5-W83R-YFP was also localized in the plasma membrane as
demonstrated by the colocalization with the Na+/K+-ATPase
resulting in a yellow coloring in the overlay picture. C.
Introduction of A153V into TGR5-YFP did not affect plasma
membrane localization. D. TGR5-V178M-YFP was also targeted
to the plasma membrane as shown by the colocalization with the
Na+/K+-ATPase fluorescence pattern. E. TGR5-A217P-YFP was
also detected in the plasma membrane as demonstrated by the
yellow coloring in the superimposed image. F. TGR5-S272G-YFP
was both localized in the plasma membrane but also in some
intracellular vesicles. Bars = 10 mm.
Found at: doi:10.1371/journal.pone.0012403.s006 (5.32 MB TIF)
Figure S5 Localization of FLAG-TGR5-YFP in HEK293 cells.
HEK293 cells were transiently transfected with the different
FLAG-TGR5-YFP constructs. The FLAG-tag was made visible
using an anti-FLAG-M2 antibody (in red). The yellow coloring in
the overlay images demonstrate that the FLAG antibody
completely binds to the FLAG-TGR5-YFP proteins both in the
plasma membrane as well as in intracellular vesicles (A–F). Nuclei
were stained with Hoechst. Bars = 10 mm.
Found at: doi:10.1371/journal.pone.0012403.s007 (4.35 MB TIF)
Figure S6 Localization of TGR5 in pcDNA in HEK293 cells.
HEK293 cells were transiently transfected with the different
TGR5 variants (without tags) and stained for TGR5 using the
anti-TGR5 (M39) antibody (shown in red). An antibody against
Na+/K+-ATPase was used as a marker for the plasma membrane
(shown in green). Nuclei were stained with Hoechst (blue).
Wildtype TGR5 (TGR5-WT) was almost completely targeted to
the plasma membrane. All TGR5-variants were also localized in
the plasma membrane of HEK293 cells as demonstrated by the
colocalization with the fluorescence from the Na+/K+-ATPase
antibody.
Found at: doi:10.1371/journal.pone.0012403.s008 (4.21 MB
TIF)
Figure S7 Localization of TGR5 in pcDNA in MDCK cells.
TGR5 variants were transfected into polarized MDCK cells.
TGR5 and TGR5 mutants were all detected in the plasma
membrane using the anti-TGR5 antibody (M39 in red).
Bars = 10 mm.
Found at: doi:10.1371/journal.pone.0012403.s009 (1.29 MB TIF)
Figure S8 Transfection efficacy of TGR5-YFP in HEK293 cells.
HEK293 cells were transiently transfected with TGR5-YFP.
Transfection efficacy was determined by flow cytometry.
Found at: doi:10.1371/journal.pone.0012403.s010 (0.10 MB TIF)
Figure S9 TGR5 expression in Epstein-Barr-virus-transformed
lymphoblastoid cell lines according to rs3731859 genotypes in all
non-related HapMap individuals (n = 210). Expression levels were
retrieved from the GENEVAR project. Genotypes and height of
expression were significantly correlated (r2 = 0.048, p = 0.0015) in
a linear regression analysis performed in SNPexp v1.1 (http://
app3.titan.uio.no/biotools/tool.php?app = snpexp, which utilizes
Plink v1.06).
Found at: doi:10.1371/journal.pone.0012403.s011 (0.04 MB TIF)
Table S1 Details of the nine primer pairs used in TGR5
resequencing (M13-primer-sequence underlined).
Found at: doi:10.1371/journal.pone.0012403.s012 (0.04 MB
DOC)
Note S1 List of members in the IBSEN study group.
Found at: doi:10.1371/journal.pone.0012403.s013 (0.03 MB
DOC)
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